PPARG and cardiovascular disorder: However, PPARγ agonists have been found in clinical trials to increase the risk of water-sodium retention, osteoporosis, adipocyte hyperplasia, and myocardial hypertrophy, which greatly limits their applications in patients with cardiovascular disease [33, 34].